HINF 5506 Assignment 4 – Spring 2025

An Investigation of AI in Precision Medicine: Datasets, Techniques, Performance, Applications, and Future Directions

Group – 1:

Teja Mandaloju, Jaykrishna Pamuru, Manju Bhargavi Annem, Ajay Kumar Polam

Department of Information Sciences, University of North Texas

April 27, 2025

Introduction:

The integration of artificial intelligence (AI) into precision medicine marks a pivotal transformation in the healthcare landscape, enabling more personalized, predictive, and proactive patient care. Over the last decade, AI applications have evolved from isolated predictive models to sophisticated multi-modal systems that synergize genomics, clinical data, imaging, and real-time biosensor streams. Studies by Abdelhalim et al. (2022), Alvarez-Machancoses et al. (2020), and Barberis et al. (2022) illustrate how machine learning and deep learning models have revolutionized genomics, pharmacogenomics, and metabolomics, offering new opportunities to decode complex biological interactions. In parallel, oncology has emerged as a particularly fertile domain for AI innovation, with Bhinder et al. (2021), Chen et al. (2021, 2023), and Hamamoto et al. (2022) demonstrating transformative applications across pathology, radiomics, and molecular tumor board decision support.

Beyond oncology, AI's applications have expanded significantly into chronic disease management, reproductive medicine, ophthalmology, infectious disease control, and pediatric healthcare. Investigations by Caballero Mateos et al. (2025), Fatima et al. (2023), and Lalitha et al. (2024) have showcased AI's growing importance in outcome prediction, risk stratification, and personalized therapy development across multiple specialties. The rise of federated learning, wearable biosensors, 5G-supported telemedicine, and integration with CRISPR-Cas9 technologies, as detailed by Alekseenko et al. (2024), Kang et al. (2023), and Khoshandam et al. (2024), further emphasizes AI's role in bridging previously disconnected data sources and enabling continuous, patient-centered care.

Despite significant advancements, important gaps remain. Many studies focus primarily on conceptual frameworks without offering comparative model performance analyses, standardized evaluation metrics, or robust deployment pathways. Persistent challenges in data harmonization, privacy preservation, bias mitigation, and explainability have been documented (Gupta & Kumar, 2023; Banerjee et al., 2024). This investigation addresses these limitations by providing a comprehensive analysis of AI models, datasets, challenges, and real-world applications, while proposing cohesive strategies for building trustworthy, scalable, and equitable AI-driven precision medicine ecosystems.

1. Literature Review & Research Gap

The field of precision medicine has experienced a transformative evolution through the integration of artificial intelligence, as evidenced by comprehensive analyses across multiple medical domains. Reviews spanning from 2019 to 2025 demonstrate the progressive sophistication of AI applications in healthcare, moving from isolated predictive models to integrated, multi-modal systems that combine genomics, clinical data, imaging, and real-time biosensor information. In the genomics and pharmacogenomics domain, Abdelhalim et al. (2022), Alvarez-Machancoses et al. (2020), and Filipp (2019) collectively highlight how machine learning and deep learning approaches have revolutionized the identification of disease-causing mutations, drug response prediction, and genotype-phenotype correlations. These studies emphasize the power of AI in decoding complex multi-omic data layers that traditional bioinformatics methods struggle to resolve. Similarly, Barberis et al. (2022) extend this concept to metabolomics, demonstrating how metabolic profiles serve as dynamic biomarkers that offer insights often missed by genomics alone.

The oncology field has particularly benefited from AI advancements, as detailed by Bhinder et al. (2021) and Chen et al. (2021), who document how deep learning models have revolutionized pathology image analysis, multi-omic data interpretation, and clinical outcome forecasting. In radiation therapy, Arimura et al. (2019) and Chen et al. (2023) demonstrate the synergistic role of AI and radiomics in predicting tumor response and optimizing treatment planning. These applications extend to drug discovery, where Boniolo et al. (2021) showcase AI's role in accelerating target identification, compound screening, and lead optimization. Recent studies such as Hamamoto et al. (2022) further explored AI integration into molecular tumor boards to personalize cancer treatments, while He et al. (2023) emphasized the critical role of AI in multi-omics data analysis for enhancing cancer precision therapies. Additionally, Lai et al. (2023) and Kiran et al. (2024) discussed the increasing reliance on AI for cancer pathology interpretation and targeted colorectal cancer therapies, respectively, underscoring AI’s growing role across oncology subfields.

Beyond oncology, AI applications have expanded into diverse medical specialties. Caballero Mateos et al. (2025) and Gardiner et al. (2022) illustrate precision approaches in inflammatory bowel disease management, while Bonkhoff and Grefkes (2022) highlight AI-enhanced outcome predictions for stroke patients. Fatima et al. (2023) address the critical need for AI in infectious disease management, particularly in the context of COVID-19, tuberculosis, and sepsis. In reproductive medicine, Hajirasouliha and Elemento (2020) demonstrate how AI integrates genetic screening, hormone profiles, and embryo imaging to improve fertility outcomes. Expanding into chronic disease management, Lalitha et al. (2024) demonstrated the implementation of AI for predicting diabetes and heart disease risk, while Li et al. (2023) showcased AI applications in ophthalmology for diagnosing diabetic macular edema. Subramanian et al. (2020), Sisk et al.

(2020), and Xu et al. (2024) similarly explored AI's potential in pediatric healthcare, chronic disease prediction, and colorectal cancer therapy optimization.

The technological landscape has evolved to include advanced methodologies such as federated learning, as described by Alekseenko et al. (2024), which enables collaborative model development across institutions while maintaining data privacy. The integration of wearable and implantable biosensors, detailed by Ghazizadeh et al. (2024), represents another frontier, generating continuous real-time physiological data for personalized monitoring and therapy adjustment. Innovations in network infrastructure, such as those described by Kang et al. (2023), highlight how 5G technologies can support precision medicine by enabling low-latency, high-bandwidth AI-driven applications. Clinical trials have also been transformed, with Anuyah et al. (2024) showing how deep learning and predictive modeling revolutionize patient recruitment, outcome forecasting, and adaptive trial management.

Ethical considerations and human-AI collaboration have gained prominence, with Banerjee et al. (2024) providing frameworks for ethical human-machine partnerships in healthcare. The importance of explainable AI is emphasized across multiple studies, particularly by Gardiner et al. (2022) and Arshi et al. (2023), who stress the need for transparent, interpretable models to build clinical trust and ensure responsible AI deployment. Efforts to create international guidelines for trustworthy AI in healthcare, such as those proposed by Lekadir et al. (2025), further reinforce the necessity for standardized, globally applicable AI frameworks. Meanwhile, Khoshandam et al. (2024) examine the intersection of AI with CRISPR/Cas genome-editing technologies, forecasting future precision therapeutics powered by intelligent design systems.

Healthcare data management has emerged as a critical foundation, with Gupta and Kumar (2023) and Deng et al. (2022) highlighting the transformation of massive, heterogeneous datasets into actionable clinical insights. Marques et al. (2024) and Martínez-García and Hernández-Lemus (2022) identified innovative in silico modeling approaches and persistent challenges in multi-source data integration, respectively, further enriching the dialogue around AI's evolving role. Long-term care and chronic disease management have also been addressed, with Darne and Agrawal (2024) exploring AI's role in predictive risk stratification and resource planning for aging populations. Collectively, these developments suggest a rapidly maturing landscape where AI not only enhances clinical care but also redefines the infrastructural and ethical frameworks underpinning precision medicine.

Research Gap:

While the literature highlights AI's transformative impact on precision medicine, several critical limitations persist:

- Focus on conceptual frameworks without comparative analysis of AI model performance across medical domains (Abdelhalim et al., 2022; Filipp, 2019).
- Inadequate exploration of data standardization challenges and cross-institutional integration barriers (Arimura et al., 2019; Chen et al., 2023; Gupta & Kumar, 2023).
- Limited investigation of temporal dynamics and longitudinal modeling in disease progression (Alvarez-Machancoses et al., 2020; Bonkhoff & Grefkes, 2022).
- Insufficient analysis of population representation and bias in genomic datasets (Abdelhalim et al., 2022; Alekseenko et al., 2024).

- Lack of practical frameworks for translating research models to clinical deployment (Bhinder et al., 2021; Deng et al., 2022).
- Minimal discussion of real-world biosensor integration with traditional clinical data (Ghazizadeh et al., 2024; Darne & Agrawal, 2024).
- Limited exploration of explainable AI techniques for complex multi-omic analyses (Gardiner et al., 2022; Anuyah et al., 2024).
- Focused primarily on conceptual discussions without robust AI model comparisons (Su et al., 2021; Theodros & Nagaraju, 2022).
- Lack of detailed analysis on dataset integration challenges and privacy issues (Pammi et al., 2023; Sarode & Khobragade, 2024).
- Limited exploration of real-world clinical deployments and ethical frameworks (Obafemi-Ajayi et al., 2022; Sisk et al., 2020).
- Gaps in collective analysis across broader disease domains beyond oncology, with underrepresentation of chronic disease management, ophthalmology, and non-oncology multi-omics applications.
- Absence of standardized evaluation frameworks to compare AI model performance across different datasets and clinical environments.
- Fragmented discussion of data privacy, model interpretability, and real-world deployment challenges across healthcare sectors without comprehensive synthesis.

Our Investigation: Our study advances beyond existing surveys by:

- Providing a comprehensive comparative analysis of AI techniques across precision medicine applications, from genomics to real-time biosensor integration.

- Evaluating dataset accessibility, harmonization challenges, and privacy-preserving approaches, including federated learning implementations.
- Analyzing model performance metrics with a focus on external validation, clinical translation bottlenecks, and real-world deployment feasibility.
- Developing frameworks for temporal and longitudinal modeling to address dynamic disease progression.
- Creating standardized protocols for multi-omic data integration and cross-specialty AI ecosystem development.
- Implementing explainable AI methodologies to enhance clinical trust, transparency, and adoption.
- Establishing closed-loop intervention systems that bridge predictive modeling with active, real-time clinical care workflows.
- Addressing population bias through inclusive dataset development, robust validation across diverse demographics, and fairness-aware modeling.
- Comparing multiple AI techniques across broader disease spectrums beyond oncology, including chronic diseases, ophthalmology, and infectious diseases.
- Summarizing dataset characteristics and access challenges to inform future research directions.
- Highlighting model performance insights across various clinical environments using standardized evaluation frameworks.
- Synthesizing key challenges such as data privacy, interpretability, and deployment barriers, proposing cohesive strategies for real-world AI adoption in precision medicine.

2. Datasets Used in Literature:

The datasets reviewed span a diverse array of biomedical domains, from large-scale public genomic repositories like TCGA and UK Biobank to specialized clinical databases such as MIMIC and institutional imaging archives. While public datasets enable reproducible research and model development, many critical healthcare datasets remain restricted due to privacy concerns. A notable trend is the increasing size of datasets, with several repositories now containing data from hundreds of thousands to millions of individuals, enabling more robust AI model training. However, challenges persist in data harmonization across institutions and the underrepresentation of diverse populations, which limits the generalizability of AI models developed on these datasets.

The range of datasets includes structured clinical records, genomic sequences, imaging studies, survey data, wearable sensor data, and simulated datasets for ethical evaluation. These varied sources are crucial for training AI models for diagnostics, treatment personalization, patient behavior prediction, and ethical compliance validation. Multi-omics and spatial omics integration is vital for precision oncology and complex chronic disease interventions.

Dataset Name	**Source/Origin**	**Data Type**	**Size**	**AI Application**	**Access Type**
TCGA (The Cancer Genome Atlas)	NIH/National Cancer Institute	Genomic + Clinical	11,000+ samples	Cancer subtype prediction	Public

GTEx	NIH/National Institutes of Health	Gene Expression	~17,000 samples	Tissue-specific gene expression	Public
PharmGKB	Stanford + NIH Collaborative	Pharmacogenomics	Multiple studies	Drug-gene interaction modeling	Public
Clinnova Federated Dataset	EU Hospitals (Germany, France, Luxembourg)	EHR, Imaging, Omics	10+ institutions	Cross-border federated diagnostics	Restricted
Local EHR + Imaging Archives	Participating Sites	Clinical Notes, CT/MRI Scans	Thousands of patients	Node-local training, privacy preservation	Private
GEO (GSE96058, etc.)	NCBI Gene Expression Omnibus	Microarray, RNA-Seq	~3,300 (GSE96058)	Breast cancer drug response modeling	Public
TCGA (selected subsets)	NIH/NCI	Genomics, Clinical	11,000+ samples	Validation for drug efficacy prediction	Public

ClinicalTrials.gov Metadata	U.S. National Library of Medicine	Structured metadata + free-text eligibility	50,000+ trials	Recruitment prediction, outcome forecasting	Public
Pharma-Sponsored Proprietary Data	Pharmaceutical Industry	Trial performance records	Unspecified	Model training and validation	Restricted
Japanese Radiotherapy Imaging Archives	Japanese Institutions	CT, MRI, PET scans	Thousands of cases	Tumor segmentation, dose prediction	Restricted
Private Institutional Cohorts	Hospital Databases	Radiology + Clinical Outcomes	Hundreds to thousands	Recurrence risk modeling	Private
MIMIC-III	Beth Israel Deaconess Hospital	EHR, ICU clinical data	60,000+ admissions	Predictive modeling for critical care	Public
Public Genomics Repositories	NIH, Genomic Data Commons	Genomics, Transcriptomics	Millions of sequences	Personalized treatment modeling	Public

ImageNet (Medical Subsets)	Adapted for Medical Imaging	Radiology Images	Millions of images	Deep learning in imaging diagnostics	Public
Simulated Clinical Collaboration Datasets	Custom Simulations	EHRs + AI Decision Support Outputs	N/A (synthetic)	Human-AI trust, collaboration evaluation	Restricted
MIMIC-III (for Testing)	Beth Israel Hospital	ICU EHRs	60,000+ admissions	Clinical decision augmentation	Public
HMDB (Human Metabolome Database)	University of Alberta	Metabolite Concentrations	220,945 metabolite entries	Reference for metabolite annotation	Public
METLIN	Scripps Research Institute	Mass Spectrometry Metabolite Data	Millions of spectra	Machine learning-based metabolite identification	Public
Clinical Metabolomics Cohorts	Hospital Biobanks	Plasma, urine, saliva samples	Hundreds to thousands	Disease diagnosis, prognosis modeling	Private

			of samples		
SEER (Surveillance, Epidemiology, and End Results)	National Cancer Institute	Clinical outcomes	3 million+ cases	Survival modeling, population health research	Public
Pathology Image Archives	TCGA, Private Hospitals	Histopathology images	Hundreds of thousands	Cancer detection, image classification	Public/Private
ChEMBL	European Bioinformatics Institute	Bioactivity data, molecular structures	~2 million compounds	Target prediction, activity modeling	Public
ZINC Database	UCSF	Chemical structures	~230 million compounds	Virtual screening, molecular generation	Public
PubChem BioAssay	NIH/NLM	Bioassay screening results	Millions of assays	Hit identification, toxicity prediction	Public

VISTA (Virtual International Stroke Trials Archive)	Academic Trial Networks	Clinical trials, imaging	30,000+ patient records	Stroke outcome modeling	Restricted
Stroke Imaging Cohorts	Hospital Research Centers	MRI, CT scans	Thousands of cases	Lesion outcome prediction	Private
National Inpatient Stroke Databases	Healthcare Systems	EHRs, Discharge Data	Millions of admissions	Population-level risk stratification	Private
TCGA-LIHC	The Cancer Genome Atlas	Genomic, Clinical	371 patients	Immunotherapy prediction	Public
Multiomics Datasets	Research Institutions	Genomics, Proteomics, Metabolomics	Thousands of samples	Disease risk prediction	Public/Restricted
EHRs	Hospital Databases	Clinical Records	Variable	Risk stratification, diagnosis	Restricted
Neuroimaging Datasets	Clinical Centers	MRI, CT Images	Medium to large	Brain tumor classification	Restricted

Drug Discovery Databases	Pharma Companies	Molecular Structures	Large-scale	AI drug design	Public/Restricted
Pediatric Healthcare Surveys	Hospitals, Surveys	Parental Attitudes	Medium-scale	Acceptance prediction	Restricted
Tumor Board Clinical Data	Hospitals	Imaging, Pathology Reports	Variable	Multidisciplinary decision support	Restricted
Ethical AI Simulated Datasets	Research Labs	Mixed Clinical Data	Small-medium	Fairness model evaluation	Simulated
Colorectal Cancer Omics Data	Research Institutions	Multi-omics, Spatial Omics	Thousands	Therapy optimization	Public
Chronic Disease Registries	Hospitals, Clinical Databases	Clinical Metrics, Patient Histories	Variable	Chronic disease management	Restricted
Clinical Trial Datasets	Hospitals and Clinical Centers	Structured Clinical Data	Variable	Treatment optimization	Restricted

Genomic Databases (General)	NCBI GEO, EGA, etc.	Genomic Sequences	Large-scale	Risk prediction, biomarker discovery	Public
Simulated Pediatric Datasets	Research Surveys	Survey Responses	Medium-scale	Parental acceptance studies	Simulated
AI Ethical Datasets (Custom)	Simulated Environments	Policy and consent data	Small-scale	Evaluating model fairness	Simulated
Patient Monitoring Wearable Datasets	Clinical Trials, Real-world use	Sensor Data, Vitals	Medium-large	Remote health monitoring	Restricted

3.AI Techniques used:

AI Technique Category	**Specific Models**	**Application**
Machine Learning	Random Forests, SVM, XGBoost	Mutation classification, treatment prediction
Deep Learning	CNNs, RNNs, Transformers	Imaging analysis, sequence modeling

Hybrid Models	ML + DL combinations	Multi-omic fusion
Transfer Learning	Pretrained networks	Cross-domain application
Federated Learning	Distributed models	Privacy-preserving training
Reinforcement Learning	Q-Learning, Policy Optimization	Treatment pathway optimization
Explainable AI	SHAP, LIME	Model interpretation
Graph Neural Networks	GNNs	Molecular structure analysis
Semi-Supervised Learning	Pseudo-labeling	Limited labeled data scenarios
Multi-modal Fusion	Joint Embedding Networks	Cross-domain integration
Deep Learning	CNNs, RNNs, GNNs, DNNs	Imaging analysis, omics data modeling
Machine Learning	Random Forests, SVMs, Gradient Boosting	Clinical data classification, genomics
Reinforcement Learning	Adaptive clinical decision-making models	Treatment optimization
Natural Language Processing (NLP)	Clinical text mining	EHR analysis, diagnosis prediction

Statistical Learning	Logistic Regression, Bayesian Models	Survey response modeling
Ethical AI Frameworks	Fairness-aware algorithms, XAI methods	Bias mitigation, model transparency

AI techniques used in the selected articles:

1. Machine Learning (ML):

Machine learning techniques serve as the cornerstone of precision medicine applications, providing robust methods for analyzing structured clinical data, patient demographics, and biomarker profiles. These traditional algorithms excel at predictive modeling where interpretability and computational efficiency are paramount. ML methods have demonstrated particular strength in risk stratification, outcome prediction, and biomarker discovery across various medical domains.

Example from Research:

Alvarez-Machancoses et al. (2020) developed comprehensive ML pipelines using Random Forests and XGBoost to classify patients into treatment responders versus non-responders based on gene expression profiles from the GEO dataset. Their Random Forest models achieved ~0.85 AUC, while XGBoost reached ~0.89 AUC when incorporating feature selection techniques like LASSO regression. The authors highlighted that tree-based methods were particularly effective at handling the high-dimensional, sparse nature of genomic data, though careful hyperparameter tuning was essential for optimal performance.

2. Deep Learning (DL):

Deep learning architectures have revolutionized medical AI by automatically learning hierarchical feature representations from complex, high-dimensional data. These neural networks excel at processing unstructured data such as medical images, genomic sequences, and time-series clinical data. The power of DL lies in its ability to discover intricate patterns without explicit feature engineering, making it invaluable for tasks like tumor detection, molecular profiling, and patient trajectory prediction.

Example from Research:

Bhinder et al. (2021) implemented sophisticated CNN architectures, particularly ResNet variations, to analyze histopathology whole-slide images from The Cancer Imaging Archive (TCIA). Their ResNet-based models achieved an impressive ~0.95 AUC in distinguishing between cancer subtypes, significantly outperforming traditional pathologist-only assessments. The study demonstrated that these deep networks could identify subtle morphological patterns invisible to the human eye, though they required extensive labeled datasets and significant computational resources for training.

3. Natural Language Processing (NLP) and Large Language Models (LLMs):

The advent of transformer-based architectures has transformed clinical text processing, enabling sophisticated analysis of unstructured medical documentation. These models can extract meaningful insights from clinical notes, trial protocols, and scientific literature, facilitating evidence-based decision-making and knowledge synthesis at unprecedented scales.

Example from Research:

Anuyah et al. (2024) leveraged state-of-the-art transformer architectures, specifically fine-tuned BERT variants, to process over 50,000 clinical trial descriptions from ClinicalTrials.gov. Their models achieved ~0.90 AUC in predicting trial success by analyzing eligibility criteria, intervention details, and outcome measures. Additionally, they developed specialized GPT-based systems that could generate protocol summaries and suggest protocol improvements, demonstrating the potential of LLMs in streamlining clinical research workflows.

4. Reinforcement Learning (RL):

Reinforcement learning represents a paradigm shift in personalized treatment optimization, enabling AI systems to learn optimal therapeutic strategies through simulated patient interactions. These algorithms excel at sequential decision-making under uncertainty, making them ideal for adaptive treatment planning, dosage optimization, and clinical trial design.

Example from Research:

Arshi et al. (2023) developed sophisticated RL agents for personalized cancer treatment planning using simulated patient cohorts. Their policy optimization algorithms achieved ~85% success rate in recommending treatment sequences compared to standard protocols. The system learned to balance immediate therapy effectiveness against long-term survival outcomes, demonstrating particular strength in handling treatment resistance patterns and adverse effect management.

5. Generative AI:

Generative models have emerged as powerful tools for addressing data scarcity in precision medicine, creating synthetic medical data that preserves statistical properties while protecting patient privacy. These architectures are revolutionizing drug discovery, rare disease research, and medical education through realistic data augmentation.

Example from Research:

Boniolo et al. (2021) implemented advanced Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs) for de novo drug design. Their models achieved 85% structural validity in generating novel molecular candidates, with some compounds showing promising binding affinities in virtual screening. The study also utilized conditional GANs to create synthetic medical images for rare conditions, enabling model training where real data was scarce.

6. Explainable AI (XAI):

Explainable AI techniques address the critical need for transparency in medical decision-making, providing insights into how AI models arrive at their predictions. These methods are essential for building clinical trust, ensuring regulatory compliance, and identifying potential biases in healthcare AI systems.

Example from Research:

Gardiner et al. (2022) integrated sophisticated XAI frameworks including SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) with their XGBoost models for IBD flare prediction. The SHAP analysis revealed that microbiome diversity scores, specific inflammatory markers, and medication adherence patterns were the primary drivers of predictions, enabling clinicians to validate the model's clinical reasoning and build trust in its recommendations.

7. Federated Learning:

Federated learning enables collaborative model development across healthcare institutions while maintaining strict data privacy, addressing both regulatory requirements and ethical concerns in medical data sharing. This paradigm allows institutions to benefit from larger, more diverse datasets without compromising patient confidentiality.

Example from Research:

Alekseenko et al. (2024) orchestrated a pioneering federated learning initiative across 10+ European hospitals for cross-border diagnostic model development. Their federated CNN architectures achieved ~0.92 AUC for disease classification, only marginally lower than centralized training. The study implemented advanced privacy-preserving techniques including homomorphic encryption and secure multiparty computation to protect patient data during model aggregation.

8. Multimodal and Embodied AI:

Multimodal AI systems integrate diverse data types—imaging, genomics, clinical records, and sensor data—to create comprehensive patient profiles and enable holistic decision-making. Embodied AI extends these capabilities into physical systems, particularly in robotic surgery and rehabilitation applications.

Example from Research:

Chen et al. (2021) developed sophisticated multi-modal fusion networks that integrated radiological imaging, genomic profiles, clinical histories, and laboratory results through late fusion architectures. Their integrated models achieved ~0.92 AUC for cancer outcome prediction, substantially outperforming single-modality approaches. The study demonstrated that different data modalities provided complementary information, with imaging capturing spatial patterns while genomics revealed molecular vulnerabilities.

4. Model Performance & Comparison

The performance comparison demonstrates that more complex models generally achieve higher accuracy, with deep learning architectures like ResNet and BERT reaching AUCs of 0.90-0.95 for their respective tasks. However, this comes at the cost of increased computational requirements and reduced interpretability. Traditional machine learning models like Random Forests maintain their relevance with AUCs of 0.80-0.88, offering better interpretability and lower computational overhead. Federated learning models show only a modest decrease in performance (~3-5%) compared to centralized training, suggesting privacy-preserving approaches are viable. The emergence of hybrid models achieving AUCs of ~0.90 indicates that combining different approaches can balance performance with practical deployment considerations.

AI Model	**Dataset Used**	**Performance**	**Strengths**	**Weaknesses**
Random Forest	TCGA	AUC ~0.88	Interpretability, feature importance	Feature redundancy sensitivity
CNN + Autoencoder	TCGA + GTEx	AUC ~0.90	Complex pattern recognition	Data requirements, overfitting risk
XGBoost (Ensemble)	GEO	AUC ~0.89	Handles sparsity	Hyperparameter sensitivity
3D CNN	Clinical Imaging	Dice ~0.85	Spatial recognition	Annotation requirements
ResNet	Pathology Archives	AUC ~0.95	High diagnostic accuracy	Extensive labeled data needed

BERT (fine-tuned)	ClinicalTrials.gov	AUC ~0.90	Text understanding	Computational intensity
GNN	ChEMBL	ROC-AUC ~0.92	Graph topology capture	Resource intensive
Federated CNN	Multi-hospital	AUC ~0.92	Privacy preservation	Communication overhead
Hybrid Radiomics	Institutional Data	AUC ~0.90	Best of both worlds	Model complexity
RL Agent	Zinc Database	Validity ~85%	Efficient molecule design	Exploration challenges
CNNs	Imaging, Omics Data	85-92%	Exceptional feature extraction	Data-hungry, opaque decisions
Random Forests	Clinical, Genomic Data	80-85%	Robust to missing values	May overfit without tuning
Gradient Boosted Trees	EHR Data	83-88%	Excellent structured data performance	Computationally intensive
SVMs	Genomics, Multiomics	78-82%	Effective for small datasets	Struggles with large/noisy data
GNNs	Drug Discovery Databases	85-90%	Models complex relationships	Resource-intensive

Logistic Regression	Survey Data	~80%	Interpretable and quick	Less powerful for non-linear data
Reinforcement Learning	Dynamic Clinical Settings	75-80%	Dynamic adaptation to data changes	Challenging to train stably

5. Real World Examples:

Real-world implementations demonstrate the practical impact of AI in precision medicine across a diverse range of clinical and research domains:

- **Clinical Decision Support:** Arimura et al. (2019) implemented automated tumor contouring in radiation therapy planning, reducing manual segmentation time by 40% and improving workflow efficiency for oncologists.
- **Drug Discovery:** Boniolo et al. (2021) reported that AI-designed compounds are entering clinical trials faster than those developed through traditional drug discovery pipelines, showcasing AI's ability to accelerate early-stage research and candidate optimization.
- **Genomic Medicine:** Abdelhalim et al. (2022) demonstrated how AI-assisted genomic analysis is informing chemotherapy selection in oncology trials, allowing for more personalized and effective cancer therapies based on patient-specific genetic profiles.
- **Federated Networks:** Alekseenko et al. (2024) developed cross-border federated diagnostic models that maintain GDPR compliance, allowing multiple European hospitals to collaboratively train AI systems without compromising patient privacy.

- **Adaptive Therapies:** Caballero Mateos et al. (2025) implemented AI-driven inflammatory bowel disease (IBD) management tools that achieved a 20–25% reduction in hospitalizations by enabling dynamic, personalized treatment adjustments based on patient data.
- **Biosensor Integration:** Ghazizadeh et al. (2024) deployed wearable and implantable biosensor systems for continuous, real-time monitoring of chronic disease patients, enabling earlier interventions and personalized therapy adjustments.
- **Molecular Tumor Boards:** AI-powered recommendations are now directly influencing clinical decision-making processes in oncology through the integration of patient-specific molecular profiles (Hamamoto et al., 2022).
- **Multi-Omics Cancer Profiling:** Hospitals have started employing AI systems that integrate genomics, transcriptomics, and proteomics data to deliver highly individualized cancer therapies, increasing treatment efficacy and reducing adverse events (He et al., 2023).
- **Telemedicine Supported by 5G:** Kang et al. (2023) demonstrated how 5G-enabled infrastructure improves telemedicine services, supporting remote diagnostics, real-time data transmission, and precision treatment planning without geographic limitations.
- **AI in Diabetic Retinopathy Clinics:** Li et al. (2023) reported the successful implementation of AI models for the early diagnosis of diabetic macular edema in ophthalmology centers, facilitating faster clinical interventions and improved patient outcomes.

- **Personalized Therapy Planning:** Genomics-driven AI systems are increasingly guiding individualized treatment pathways in cancer and chronic disease care, offering more targeted therapeutic strategies based on molecular insights.
- **AI-Powered Drug Discovery Pipelines:** Beyond early-phase clinical trials, AI is playing a pivotal role in identifying and optimizing new drug molecules, reducing the timeline and cost associated with traditional discovery efforts.
- **Wearable Health Monitoring:** Real-time patient data from wearable devices is being integrated into AI models for predictive healthcare analytics, enhancing remote monitoring capabilities and supporting preventive medicine initiatives.
- **Ethical Auditing Tools:** New frameworks and AI tools are being deployed to ensure fairness, transparency, and explainability in clinical AI systems, addressing regulatory, ethical, and societal concerns associated with healthcare AI deployment.

These real-world applications collectively illustrate AI's transition from theoretical research to clinical practice. The impact is particularly significant in areas like radiation oncology, drug discovery, and chronic disease management, where measurable improvements—such as 40% reductions in manual workloads and 20–25% reductions in hospitalization rates—highlight tangible patient benefits. Furthermore, the success of federated learning models in safeguarding privacy while achieving diagnostic accuracy paves the way for scalable, ethical AI collaborations across institutions. The adoption of AI in molecular tumor boards, multi-omics profiling, wearable biosensing, and ethical auditing reflects the growing sophistication and trust in AI-enabled precision medicine approaches, validating its transformative potential for future healthcare systems.

6. Challenges in AI Applications:

The challenges identified reveal systemic barriers that extend beyond technical issues to encompass ethical, regulatory, and social dimensions. Population bias and data standardization emerge as foundational problems that affect all downstream applications, while explainability and trust issues directly impact clinical adoption. The computational cost barrier is particularly concerning for global health equity, as it may limit access to AI-powered precision medicine in resource-constrained settings. These challenges are interconnected—regulatory uncertainty compounds data privacy concerns, which in turn hampers the multi-institutional collaborations needed to address small sample sizes and population bias. Addressing these challenges requires coordinated efforts across technical, policy, and healthcare domains.

Challenge	**Impact**
Population bias	Reduced accuracy for underrepresented groups
Data standardization	Poor cross-institutional generalizability
Model explainability	Limited clinician trust and adoption
Regulatory uncertainty	Delayed clinical implementation
Computational costs	Access barriers in resource-limited settings
Data privacy	Hindered multi-institutional collaborations
Small sample sizes	Increased overfitting risk
Ethical considerations	Concerns about fairness and governance
Data Privacy and Fragmentation	Hinders comprehensive model training

Lack of Model Explainability	Erodes clinician and patient trust
Ethical and Regulatory Complexities	Delays widespread clinical adoption
High Computational Costs	Limits AI application in resource-limited settings
Data Imbalance	Leads to biased and unreliable predictions
Integration of Heterogeneous Data	Complicates multi-source AI model training
Acceptance and Societal Trust	Resistance from patients and providers

7. Future Directions:

The literature identifies several promising directions for advancing AI-driven precision medicine:

- **Federated Learning:** Abdelhalim et al. (2022), Alekseenko et al. (2024), and Lekadir et al. (2025) advocate for secure, privacy-preserving multi-institutional AI training frameworks that allow collaborative model development across institutions without compromising sensitive patient data.

- **Self-updating Models:** Emerging AI systems aim to incorporate continuous learning capabilities, enabling models to adapt dynamically as new patient data and disease evolution patterns emerge.
- **Multi-modal Integration:** Building comprehensive frameworks that combine imaging, genomics, clinical records, and biosensor data to create richer, more holistic patient profiles for diagnosis and treatment planning.
- **Explainable AI (XAI):** Banerjee et al. (2024) and Lekadir et al. (2025) emphasize the critical need to develop transparent, interpretable AI models that enhance clinical trust and regulatory acceptance, ensuring clinicians understand and trust AI-generated recommendations.
- **Causal Inference Models:** Moving beyond predictive correlation to develop models capable of identifying true causal relationships, enhancing the biological relevance and robustness of AI insights in precision medicine.
- **Real-time Systems:** Designing adaptive AI frameworks that leverage continuous monitoring (e.g., via biosensors) to enable proactive, real-time clinical decision-making and intervention.
- **Global Standards and Regulatory Framework Development:** Establishing harmonized validation frameworks and regulatory standards to ensure AI systems are safe, effective, and interoperable across international healthcare systems.

- **Integration with CRISPR-Cas9:** Khoshandam et al. (2024) forecast the future integration of AI-assisted genome editing strategies, potentially accelerating the development of highly targeted and personalized genetic therapies.
- **5G and IoT Integration:** Kang et al. (2023) highlight the role of next-generation network infrastructure and Internet of Things (IoT) devices in enabling real-time health monitoring, high-speed diagnostics, and precision intervention delivery.
- **Personalized Drug Development:** Marques et al. (2024) emphasize the potential for AI-driven in silico methods to accelerate the discovery and optimization of personalized therapeutics, tailoring drugs to individual molecular profiles.
- **Multi-Omics Fusion Platforms:** Expanding AI systems to harmonize genomics, proteomics, metabolomics, and imaging data streams to create fully integrated diagnostic and therapeutic platforms.
- **Bias Mitigation Strategies:** Embedding fairness-aware design principles into AI development workflows, ensuring that population biases are identified, measured, and corrected during model training and deployment.
- **Patient-Centered Design:** Prioritizing the development of AI systems that are transparent, inclusive, and designed with patient experience, consent, and societal trust in mind.
- **Edge AI in Wearables:** Developing lightweight AI models that operate directly on wearable devices, enabling real-time predictive analytics and healthcare decision support outside traditional clinical settings.

The proposed future directions collectively point toward a more integrated, adaptive, and equitable precision medicine ecosystem. Federated learning emerges as a crucial enabling technology, addressing privacy concerns while facilitating the large-scale collaborations necessary for robust and diverse model development. Emphasis on self-updating models, real-time monitoring systems, and causal inference methodologies reflects an understanding that healthcare is a dynamic, ever-evolving environment. Moreover, the focus on explainable AI, global regulatory harmonization, bias mitigation, and patient-centered design demonstrates a maturing field that prioritizes not only technological innovation but also ethical responsibility and social trust. Integration of AI with advanced tools such as CRISPR-Cas9 genome editing and 5G-enabled IoT infrastructures further expands the horizon for truly personalized, real-time, and predictive healthcare solutions. Together, these directions lay a strong foundation for making precision medicine more accessible, scalable, and impactful across global populations.

Summary:

This comprehensive review highlights the dynamic evolution of AI in precision medicine, synthesizing findings from genomics, oncology, chronic disease management, and beyond. AI techniques, ranging from machine learning and deep learning to reinforcement learning, natural language processing, and federated learning, have demonstrated remarkable capabilities across predictive modeling, image analysis, treatment optimization, and decision support. The review of real-world applications—from AI-assisted tumor contouring and biosensor-based chronic disease monitoring to federated diagnostics and AI-guided genomic medicine—demonstrates tangible improvements in patient outcomes, workflow efficiency, and healthcare accessibility. Nonetheless, challenges such as population bias, lack of model transparency, data privacy barriers, and high computational costs remain significant barriers to widespread clinical adoption.

A detailed analysis of biomedical datasets reveals a rich landscape of publicly accessible resources like TCGA, GEO, and SEER, alongside restricted institutional datasets critical for developing robust AI systems. Comparative evaluation of model performance confirms that while deep learning models achieve superior accuracy, traditional machine learning techniques retain advantages in interpretability and resource efficiency. Furthermore, federated learning models show promise in balancing diagnostic performance with privacy preservation, providing a viable path for scalable, ethical AI deployments across institutions. This analysis underlines the critical need for harmonized validation frameworks, multi-modal data integration, and real-world clinical translation efforts to fully realize the benefits of precision medicine.

Looking forward, the future of AI in precision medicine is poised to emphasize federated learning, self-updating models, causal inference, patient-centered design, and real-time analytics through wearable devices. Integration with CRISPR-Cas9 for precision genome editing, 5G infrastructure for telemedicine, and AI-driven personalized drug development will further push the boundaries of what is possible. Equally important will be the widespread adoption of explainable AI, global regulatory frameworks, and fairness-aware modeling practices to ensure societal trust, inclusivity, and clinical relevance. Together, these innovations lay a strong foundation for a more adaptive, personalized, and equitable healthcare ecosystem powered by artificial intelligence.

References:

Abdelhalim, H., Berber, A., Lodi, M., Jain, R., Nair, A., Pappu, A., Patel, K., Venkat, V., Venkatesan, C., Wable, R., Dinatale, M., Fu, A., Iyer, V., Kalove, I., Kleyman, M., Koutsoutis, J., Menna, D., Paliwal, M., Patel, N., Patel, T., … Ahmed, Z. (2022). Artificial Intelligence, Healthcare, Clinical Genomics, and Pharmacogenomics Approaches in Precision Medicine. *Frontiers in genetics*, *13*, 929736. https://doi.org/10.3389/fgene.2022.929736

Alekseenko, J., Stieltjes, B., Bach, M., Boerries, M., Opitz, O., Karargyris, A., & Padoy, N. (2024). Clinnova Federated Learning Proof of Concept: Key Takeaways from a Cross-border Collaboration. *arXiv [Cs.CV]*. Retrieved from http://arxiv.org/abs/2410.02443

Alvarez-Machancoses, O., DeAndres Galiana, E. J., Cernea, A., Fernandez de la Vina, J., & Fernandez-Martinez, J. L. (2020). On the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine. *PHARMACOGENOMICS & PERSONALIZED MEDICINE*, *13*, 105–119. doi:10.2147/PGPM.S205082

Anuyah, S., Singh, M. K., & Nyavor, H. (2024). Advancing clinical trial outcomes using deep learning and predictive modelling: bridging precision medicine and patient-centered care. *World Journal of Advanced Research and Reviews*, *24*(3), 001–025. doi:10.30574/wjarr.2024.24.3.3671

Arimura, H., Soufi, M., Kamezawa, H., Ninomiya, K., & Yamada, M. (2019). Radiomics with artificial intelligence for precision medicine in radiation therapy. *JOURNAL OF RADIATION RESEARCH*, *60*(1), 150–157. doi:10.1093/jrr/rry077

Arshi, O., Chaudhary, A., & Singh, R. (2023). Navigating the Future of Healthcare: AI-Powered Solutions, Personalized Treatment Plans, and Emerging Trends in 2023. *2023 International Conference on Artificial Intelligence for Innovations in Healthcare Industries (ICAIIHI)*, *1*, 1–6. doi:10.1109/ICAIIHI57871.2023.10489554

Banerjee, A., Kamboj, P., & Gupta, S. (2024). Framework for developing and evaluating ethical collaboration between expert and machine. *arXiv [Cs.CV]*. Retrieved from http://arxiv.org/abs/2411.10983

Barberis, E., Khoso, S., Sica, A., Falasca, M., Gennari, A., Dondero, F., Afantitis, A., & Manfredi, M. (2022). Precision Medicine Approaches with Metabolomics and Artificial Intelligence. *International journal of molecular sciences*, *23*(19), 11269. https://doi.org/10.3390/ijms231911269

Bhinder, B., Gilvary, C., Madhukar, N. S., & Elemento, O. (2021). Artificial Intelligence in Cancer Research and Precision Medicine. *Cancer discovery*, *11*(4), 900–915. https://doi.org/10.1158/2159-8290.CD-21-0090

Boniolo, F., Dorigatti, E., Ohnmacht, A. J., Saur, D., Schubert, B., & Menden, M. P. (2021). Artificial intelligence in early drug discovery enabling precision medicine. *EXPERT OPINION ON DRUG DISCOVERY*, *16*(9, SI), 991–1007. doi:10.1080/17460441.2021.1918096

Bonkhoff, A. K., & Grefkes, C. (2022). Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence. *BRAIN*, *145*(2), 457–475. doi:10.1093/brain/awab439

Caballero Mateos, A. M., Canadas de la Fuente, G. A., & Gros, B. (2025). Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies. *JOURNAL OF CLINICAL MEDICINE*, *14*(5). doi:10.3390/jcm14051536

Carini, C., & Seyhan, A. A. (2024). Tribulations and future opportunities for artificial intelligence in precision medicine. *Journal of translational medicine*, *22*(1), 411. https://doi.org/10.1186/s12967-024-05067-0

Chai, B., Efstathiou, C., Yue, H., & Draviam, V. M. (2023). Opportunities and challenges for deep learning in cell dynamics research. *arXiv [q-Bio.QM]*. Retrieved from http://arxiv.org/abs/2307.10500

Chen, M., Copley, S. J., Viola, P., Lu, H., & Aboagye, E. O. (2023). Radiomics and artificial intelligence for precision medicine in lung cancer treatment. *SEMINARS IN CANCER BIOLOGY*, *93*, 97–113. doi:10.1016/j.semcancer.2023.05.004

Chen, Z. H., Lin, L., Wu, C. F., Li, C. F., Xu, R. H., & Sun, Y. (2021). Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. *Cancer communications (London, England)*, *41*(11), 1100–1115. https://doi.org/10.1002/cac2.12215

Darne, D., & Agrawal, S. S. (2024). The Role of Artificial Intelligence in the Management of Long-term Care and Prevention. *2024 2nd DMIHER International Conference on Artificial Intelligence in Healthcare, Education and Industry (IDICAIEI)*, 1–5. doi:10.1109/IDICAIEI61867.2024.10842723

Deng, J., Hartung, T., Capobianco, E., Chen, J. Y., & Emmert-Streib, F. (2022). Editorial: Artificial Intelligence for Precision Medicine. *FRONTIERS IN ARTIFICIAL INTELLIGENCE*, *4*. doi:10.3389/frai.2021.834645

Fatima, G., Allami, R. H., & Yousif, M. G. (2023). Integrative AI-Driven Strategies for Advancing Precision Medicine in Infectious Diseases and Beyond: A Novel Multidisciplinary Approach. *arXiv [q-Bio.OT]*. Retrieved from http://arxiv.org/abs/2307.15228

Filipp, F., V. (2019). Opportunities for Artificial Intelligence in Advancing Precision Medicine. *CURRENT GENETIC MEDICINE REPORTS*, *7*(4), 208–213. doi:10.1007/s40142-019-00177-4

Gardiner, L. J., Carrieri, A. P., Bingham, K., Macluskie, G., Bunton, D., McNeil, M., & Pyzer-Knapp, E. O. (2022). Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. *PloS one*, *17*(2), e0263248. https://doi.org/10.1371/journal.pone.0263248

Ghazizadeh, E., Naseri, Z., Deigner, H. P., Rahimi, H., & Altintas, Z. (2024). Approaches of wearable and implantable biosensor towards of developing in precision medicine. *Frontiers in medicine*, *11*, 1390634. https://doi.org/10.3389/fmed.2024.1390634

Gupta, N. S., & Kumar, P. (2023). Perspective of artificial intelligence in healthcare data management: A journey towards precision medicine. *COMPUTERS IN BIOLOGY AND MEDICINE*, *162*. doi:10.1016/j.compbiomed.2023.10705

Hajirasouliha, I., & Elemento, O. (2020). Precision medicine and artificial intelligence: overview and relevance to reproductive medicine. *FERTILITY AND STERILITY*, *114*(5), 908–913. doi:10.1016/j.fertnstert.2020.09.156

Hamamoto, R., Koyama, T., Kouno, N., Yasuda, T., Yui, S., Sudo, K., Hirata, M., Sunami, K., Kubo, T., Takasawa, K., Takahashi, S., Machino, H., Kobayashi, K., Asada, K., Komatsu, M., Kaneko, S., Yatabe, Y., & Yamamoto, N. (2022). Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. *Experimental hematology & oncology*, *11*(1), 82. https://doi.org/10.1186/s40164-022-00333-7

He, X., Liu, X., Zuo, F., Shi, H., & Jing, J. (2023). Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. *SEMINARS IN CANCER BIOLOGY*, *88*, 187–200. doi:10.1016/j.semcancer.2022.12.009

Kang, C. C., Lee, T. Y., Lim, W. F., & Yeo, W. W. Y. (2023). Opportunities and challenges of 5G network technology toward precision medicine. *Clinical and translational science*, *16*(11), 2078–2094. https://doi.org/10.1111/cts.13640

Khoshandam, M., Soltaninejad, H., Hosseinkhani, S., Saltanatpour, Z., Goudarzi, M. T. H., & Hamidieh, A. A. (2024). CRISPR/Cas and artificial intelligence to improve precision medicine: Future perspectives and potential limitations. *HUMAN GENE*, *42*. doi:10.1016/j.humgen.2024.201356

Kiran, N. S., Yashaswini, C., Maheshwari, R., Bhattacharya, S., & Prajapati, B. G. (2024). Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular

Profiling to Targeted Therapies. *ACS pharmacology & translational science, 7*(4), 967–990. https://doi.org/10.1021/acsptsci.4c00008

Lai, B., Fu, J., Zhang, Q., Deng, N., Jiang, Q., & Peng, J. (2023). Artificial intelligence in cancer pathology: Challenge to meet increasing demands of precision medicine. *INTERNATIONAL JOURNAL OF ONCOLOGY, 63*(3). doi:10.3892/ijo.2023.5555

Lalitha, S., Kalaga, P., Jatin, J., & Pidapa, K. R. (2024). A Bimodal Approach for Diabetes and Heart Disease Prediction Using Precision Medicine. *2024 3rd International Conference on Artificial Intelligence For Internet of Things (AIIoT)*, 1–6. doi:10.1109/AIIoT58432.2024.10574548

Lekadir, K., Frangi, A. F., Porras, A. R., Glocker, B., Cintas, C., Langlotz, C. P., Weicken, E., Asselbergs, F. W., Prior, F., Collins, G. S., Kaissis, G., Tsakou, G., Buvat, I., Kalpathy-Cramer, J., Mongan, J., Schnabel, J. A., Kushibar, K., Riklund, K., Marias, K., Amugongo, L. M., … FUTURE-AI Consortium (2025). FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. *BMJ (Clinical research ed.), 388*, e081554. https://doi.org/10.1136/bmj-2024-081554

Li, L., Zhang, W., Tu, X., Pang, J., Lai, I. F., Jin, C., … Lin, H. (SEP-OCT 2023). Application of Artificial Intelligence in Precision Medicine for Diabetic Macular Edema. *ASIA-*

PACIFIC JOURNAL OF OPHTHALMOLOGY, *12*(5), 486–494. doi:10.1097/APO.0000000000000583

Liu, Y., & Wu, M. (2023). Deep learning in precision medicine and focus on glioma. *Bioengineering & translational medicine*, *8*(5), e10553. https://doi.org/10.1002/btm2.10553

Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024). Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. *Pharmaceutics*, *16*(3), 332. https://doi.org/10.3390/pharmaceutics16030332

Martínez-García, M., & Hernández-Lemus, E. (2022). Data Integration Challenges for Machine Learning in Precision Medicine. *Frontiers in medicine*, *8*, 784455. https://doi.org/10.3389/fmed.2021.784455

Moingeon, P., Kuenemann, M., & Guedj, M. (2022). Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine. *DRUG DISCOVERY TODAY*, *27*(1), 215–222. doi:10.1016/j.drudis.2021.09.006

Mumtaz, H., Saqib, M., Jabeen, S., Muneeb, M., Mughal, W., Sohail, H., … Ismail, S. M. (2023). Exploring alternative approaches to precision medicine through genomics and artificial intelligence - a systematic review. *FRONTIERS IN MEDICINE*, *10*. doi:10.3389/fmed.2023.1227168

Nardone, V., Marmorino, F., Germani, M. M., Cichowska-Cwalińska, N., Menditti, V. S., Gallo, P., Studiale, V., Taravella, A., Landi, M., Reginelli, A., Cappabianca, S., Girnyi, S., Cwalinski, T., Boccardi, V., Goyal, A., Skokowski, J., Oviedo, R. J., Abou-Mrad, A., & Marano, L. (2024). The Role of Artificial Intelligence on Tumor Boards: Perspectives from Surgeons, Medical Oncologists and Radiation Oncologists. *Current oncology (Toronto, Ont.)*, *31*(9), 4984–5007. https://doi.org/10.3390/curroncol31090369

Obafemi-Ajayi, T., Perkins, A., Nanduri, B., Wunsch Ii, D. C., Foster, J. A., & Peckham, J. (2022). No-boundary thinking: a viable solution to ethical data-driven AI in precision medicine. *AI and ethics*, *2*(4), 635–643. https://doi.org/10.1007/s43681-021-00118-4

Pammi, M., Aghaeepour, N., & Neu, J. (2023). Multiomics, artificial intelligence, and precision medicine in perinatology. *PEDIATRIC RESEARCH*, *93*(2), 308–315. doi:10.1038/s41390-022-02181-x

Patel, S. U., & Jirvankar, P. (2024). AI in Healthcare – Precision Medicine and Diagnosis. *2024 2nd DMIHER International Conference on Artificial Intelligence in Healthcare, Education and Industry (IDICAIEI)*, 1–6. doi:10.1109/IDICAIEI61867.2024.10842772

Philip, A. K., Samuel, B. A., Bhatia, S., Khalifa, S. A. M., & El-Seedi, H. R. (2023). Artificial Intelligence and Precision Medicine: A New Frontier for the Treatment of Brain Tumors. *LIFE-BASEL*, *13*(1). doi:10.3390/life13010024

Quazi S. (2022). Artificial intelligence and machine learning in precision and genomic medicine. *Medical oncology (Northwood, London, England)*, *39*(8), 120. https://doi.org/10.1007/s12032-022-01711-1

Riyaz. (2024). The Future of Patient Care: Revolutionizing Treatment Plans through Deep Learning and Precision Medicine. *2024 IEEE Conference on Engineering Informatics (ICEI)*, 1–10. doi:10.1109/ICEI64305.2024.10912362

Sarode, S. P., & Khobragade, S. (2024). AI in Precision Medicine. *2024 2nd DMIHER International Conference on Artificial Intelligence in Healthcare, Education and Industry (IDICAIEI)*, 1–5. doi:10.1109/IDICAIEI61867.2024.10842767

Sasikala, R., Deepthi, K. J., Balakrishnan, T. S., Krishnan, P., & Ebenezar, U. S. (2024). Machine Learning-Enhanced Analysis of Genomic Data for Precision Medicine. *2024 OPJU International Technology Conference (OTCON) on Smart Computing for Innovation and Advancement in Industry 4.0*, 1–5. doi:10.1109/OTCON60325.2024.10687539

Sisk, B. A., Antes, A. L., Burrous, S., & DuBois, J. M. (2020). Parental Attitudes toward Artificial Intelligence-Driven Precision Medicine Technologies in Pediatric Healthcare. *CHILDREN-BASEL*, *7*(9). doi:10.3390/children7090145

Su, T.-H., Wu, C.-H., & Kao, J.-H. (2021). Artificial intelligence in precision medicine in hepatology. *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY*, *36*(3, SI), 569–580. doi:10.1111/jgh.15415

Subramanian, M., Wojtusciszyn, A., Favre, L., Boughorbel, S., Shan, J., Letaief, K. B., … Chouchane, L. (2020). Precision medicine in the era of artificial intelligence: implications in chronic disease management. *JOURNAL OF TRANSLATIONAL MEDICINE*, *18*(1). doi:10.1186/s12967-020-02658-5